According to a study published in Canadian Medical Association Journal, Metformin use was related to a considerably decreased risk of complete joint replacement in those with type 2 diabetes mellitus.
Randomized controlled clinical studies are the most effective technique to establish if metformin can assist individuals with osteoarthritis in avoiding having to replace a joint.
Osteoarthritis (OA) is the primary cause of pain, discomfort, and loss of function in the elderly. Several complicated phenotypes are associated with this illness, including synovial inflammation, osteoporosis, articular cartilage degeneration, and metabolic issues. Studies suggest that persons with advanced OA typically need to replace a joint surgically.
There will be an annual demand of 572,000 total hip replacements and 3.5 million full knee replacements in the United States by 2030. There is no method to prevent or slow the progression of OA at the moment.
Metformin appears to lower significantly the frequency of complete joint replacements in the elderly, based on data from more than 40,000 individuals. Metformin adherence is related to a 30% reduction in risk of total knee or total hip replacement, according to data from 80,000 patients treated with metformin versus 80,000 people not treated with metformin.
According to Changhai Ding of the Clinical Research Center at Zhujiang Hospital, Southern Medical University in Guangzhou, China, metformin may have a therapeutic effect on patients with osteoarthritis: “we found that metformin use in patients with type 2 diabetes mellitus was associated with a significantly lower risk of joint replacement.”
As populations age around the world, steps must be taken to guarantee the health and safety of the elderly. Ding and colleagues from China, Taiwan, and Australia wanted to see if consuming metformin was linked to a lower risk of total knee or hip replacement surgery.
The Taiwan National Health Insurance Research database followed individuals diagnosed with type 2 diabetes in Taiwan between 2000 and 2012. Participants in this research had to be among the 85,455 newly diagnosed with type 2 diabetes.
Prescription time-distribution matching was utilized to connect 20,347 patients who had not been prescribed metformin with those who had. In this data collection, the average age (SD = 11) was 63, and women comprised 49.8% of the population.
By employing propensity scores, researchers could locate 10,163 groups of metformin users and nonusers to compare. The goal of this study was to utilize Cox proportional hazards regression to investigate the relationships between metformin use and the risk of having total knee and hip replacement surgery, both as a composite and as individual end goals.
Patients using metformin had a 70% reduction in the chance of requiring a total hip or knee replacement (95% CI: 0.60-0.81). Lower risks were seen when entire knee and hip replacements were analyzed separately from the primary end goal (adjusted hazard ratio [aHR], 0.71 [95% CI, 0.61-0.84] and 0.61 [95% CI, 0.41-0.92]).
Consistent findings were obtained in competing for risk regression, propensity score matching, and sensitivity analyses employing inverse probability of treatment weighting.
One Response
Thank you